Humacyte Taps Veteran Vascular Surgeon as Chief Surgical Officer
Event summary
- Humacyte appointed Dr. Todd E. Rasmussen as Chief Surgical Officer on May 12, 2026.
- Dr. Rasmussen brings 28 years of vascular surgery experience, including leadership roles in the U.S. Air Force and Mayo Clinic.
- He will focus on surgical support, education, and clinical integration of Humacyte’s products, particularly Symvess®.
- Mayo Clinic has a financial interest in Humacyte, with revenue supporting its not-for-profit mission.
The big picture
Humacyte’s appointment of Dr. Rasmussen underscores its push to strengthen clinical adoption as Symvess® and other ATEV products advance toward broader regulatory approvals. The move aligns with the biotech industry’s trend of integrating surgical expertise into leadership to bridge the gap between innovation and real-world implementation. With Mayo Clinic’s financial stake, the partnership could also enhance Humacyte’s credibility in the medical community.
What we're watching
- Clinical Adoption
- How Dr. Rasmussen’s surgical expertise will accelerate Symvess® adoption among healthcare providers.
- Regulatory Strategy
- Whether Humacyte can leverage Dr. Rasmussen’s insights to streamline approvals for pipeline indications.
- Execution Risk
- The pace at which Humacyte integrates surgical feedback into product development and commercialization.
Related topics